{
    "organizations": [],
    "uuid": "8599300a30efcef9778af363e1f614a139e7a371",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-genmab-q1-net-sales-of-darzalex-at/brief-genmab-q1-net-sales-of-darzalex-at-432-mln-idUSASO0003D7",
    "ord_in_thread": 0,
    "title": "BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Genmab A/S:\n* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018\n* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018\n* NET SALES OF DARZALEX IN Q1 OF 2018 TOTALED USD 432 MILLION\n* WILL RECEIVE ROYALTIES ON WORLDWIDE SALES FROM JANSSEN BIOTECH, INC Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-17T18:53:00.000+03:00",
    "crawled": "2018-04-18T18:26:32.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "genmab",
        "announces",
        "net",
        "sale",
        "daratumumab",
        "first",
        "quarter",
        "announces",
        "net",
        "sale",
        "daratumumab",
        "first",
        "quarter",
        "net",
        "sale",
        "darzalex",
        "q1",
        "totaled",
        "usd",
        "million",
        "receive",
        "royalty",
        "worldwide",
        "sale",
        "janssen",
        "biotech",
        "inc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}